All the news Showing 10 of 65 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources REP 2139 combination therapy leads to functional control of hepatitis B virus Liz Highleyman / 29 November 2017 A majority of people with chronic hepatitis B treated with a nucleic acid polymer (REP 2139 or REP 2165) plus tenofovir and pegylated interferon were able to achieve 'functional control' of hepatitis B ... Besifovir and tenofovir exalidex look promising as new hepatitis B drug Liz Highleyman / 04 May 2017 Two investigational nucleotide analogue antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the International Liver Congress last week in Amsterdam. ... EASL releases updated hepatitis B guidelines at International Liver Congress Liz Highleyman / 26 April 2017 The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection – the first update since 2012 – during a ... Switching to TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 26 April 2017 People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at ... Is better treatment reducing liver cancer among people with hepatitis B? Liz Highleyman / 23 February 2017 The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among people with chronic hepatitis B treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD ... Tenofovir alafenamide approved for hepatitis B in Europe Liz Highleyman / 16 January 2017 The European Commission this week granted marketing authorisation for tenofovir alafenamide, to be sold under the brand name Vemlidy, for the treatment of chronic hepatitis B virus (HBV) infection, according ... European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection Gilead press release / 11 January 2017 Nucleic acid polymers reduce HBsAg levels and improve control of hepatitis B virus Liz Highleyman / 27 November 2016 The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small ... Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones Liz Highleyman / 15 November 2016 Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ... U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection Gilead press release / 11 November 2016 ← Prev12345...7Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive